Matthew R Hayes Selected Research

Liraglutide

12/2023	A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss.
1/2020	GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats.
1/2020	Hindbrain melanocortin 3/4 receptors modulate the food intake and body weight suppressive effects of the GLP-1 receptor agonist, liraglutide.
11/2019	Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss.
1/2019	Liraglutide pharmacotherapy reduces body weight and improves glycaemic control in juvenile obese/hyperglycaemic male and female rats.
4/2012	The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.
8/2011	Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.
7/2011	Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew R Hayes Research Topics

Disease

37	Body Weight (Weight, Body) 12/2023 - 01/2010
35	Obesity 03/2024 - 08/2007
20	Nausea 03/2024 - 04/2012
17	Vomiting 03/2024 - 09/2012
11	Weight Loss (Weight Reduction) 12/2023 - 08/2007
10	Anorexia 01/2023 - 01/2016
6	Type 2 Diabetes Mellitus (MODY) 01/2022 - 12/2011
6	Pica (Geophagia) 01/2020 - 04/2012
4	Opioid-Related Disorders (Opiate Addiction) 12/2023 - 01/2021
2	Chronic Disease (Chronic Diseases) 03/2024 - 01/2023
2	Pain (Aches) 01/2023 - 01/2021
2	Weight Gain 07/2021 - 12/2011
2	AIDS-Related Complex (ARC) 01/2021 - 02/2016
2	Body Weight Changes 01/2019 - 01/2018
2	Insulin Resistance 01/2018 - 12/2011
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2017 - 08/2007
2	Hyperphagia (Overeating) 01/2015 - 01/2010
2	Cognitive Dysfunction 07/2014 - 09/2012
2	Diabetes Mellitus 07/2011 - 07/2010
1	Chronic Pain 01/2023
1	Neuroinflammatory Diseases 01/2022
1	Glaucoma 01/2022
1	Gliosis 01/2020
1	Neoplasms (Cancer) 01/2020
1	Morning Sickness 01/2020
1	Pediatric Obesity 01/2019
1	Tobacco Use Disorder (Nicotine Dependence) 05/2017
1	Feeding and Eating Disorders (Eating Disorder) 06/2016
1	Substance-Related Disorders (Drug Abuse) 06/2016
1	Cocaine-Related Disorders (Cocaine Addiction) 01/2016

Drug/Important Bio-Agent (IBA)

24	Glucagon-Like Peptide 1 (GLP 1)IBA 03/2024 - 07/2010
17	Glucagon-Like Peptide-1 ReceptorIBA 01/2023 - 03/2011
11	LeptinIBA 01/2021 - 08/2007
9	Islet Amyloid PolypeptideIBA 01/2021 - 08/2013
8	Peptides (Polypeptides)IBA 12/2023 - 08/2007
8	Glucose (Dextrose)FDA LinkGeneric 12/2023 - 01/2017
8	Liraglutide FDA Link 12/2023 - 07/2011
7	Exenatide (Byetta)FDA Link 01/2021 - 07/2011
6	Appetite Depressants (Anorectics)IBA 01/2023 - 03/2016
4	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 04/2012
4	Islet Amyloid Polypeptide ReceptorsIBA 11/2019 - 08/2013
3	AntiemeticsIBA 03/2024 - 01/2016
3	neuropeptide Y2 receptorIBA 12/2023 - 01/2021
3	Growth Differentiation Factor 15IBA 01/2023 - 01/2020
3	gastric inhibitory polypeptide receptorIBA 01/2023 - 11/2021
3	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 01/2016
3	Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric 01/2022 - 01/2018
3	LigandsIBA 11/2021 - 08/2008
3	muskIBA 11/2021 - 01/2020
3	EmeticsIBA 11/2021 - 01/2020
3	Sucrose (Saccharose)IBA 07/2021 - 01/2010
3	Pro-Opiomelanocortin (Proopiomelanocortin)IBA 05/2021 - 06/2011
3	Blood Glucose (Blood Sugar)IBA 08/2017 - 02/2014
3	Nicotine FDA Link 05/2017 - 09/2012
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 12/2023 - 10/2021
2	Hormones (Hormone)IBA 12/2023 - 12/2017
2	Peptide YYIBA 12/2023 - 01/2022
2	Opioid Analgesics (Opioids)IBA 12/2023 - 12/2021
2	Insulin (Novolin)FDA Link 12/2023 - 08/2007
2	GhrelinIBA 01/2023 - 08/2007
2	melanotan-IIIBA 05/2021 - 09/2012
2	Calcitonin Receptors (Calcitonin Receptor)IBA 01/2021 - 02/2016
2	Cocaine (Cocaine HCl)IBA 01/2021 - 01/2018
2	Dimenhydrinate (DMH)FDA LinkGeneric 01/2021 - 01/2018
2	MelanocortinsIBA 01/2020 - 09/2012
2	salmon calcitonin (Calcimar)FDA LinkGeneric 11/2019 - 12/2017
2	Proglucagon (Glucagon Precursors)IBA 11/2019 - 01/2016
2	exendin (9-39)IBA 01/2016 - 04/2012
2	Small Interfering RNA (siRNA)IBA 01/2015 - 01/2010
2	Acetylcholine (Acetylcholine Chloride)FDA Link 07/2014 - 09/2012
2	Cholecystokinin (Pancreozymin)IBA 01/2010 - 08/2007
1	Gastric Inhibitory Polypeptide (Glucose Dependent Insulinotropic Peptide)IBA 03/2024
1	NeuropeptidesIBA 12/2023
1	mu Opioid Receptors (mu Opioid Receptor)IBA 01/2023
1	corrinIBA 01/2022
1	salicylhydroxamic acid (SHAM)IBA 07/2021
1	Peptide Hormones (Polypeptide Hormones)IBA 01/2021
1	IncretinsIBA 01/2021
1	Fentanyl (Sublimaze)FDA LinkGeneric 01/2021
1	Amphetamine (Amfetamine)FDA LinkGeneric 01/2021
1	SHU 9119IBA 01/2020
1	CytokinesIBA 01/2020
1	Type 3 Melanocortin ReceptorIBA 01/2020
1	AdipokinesIBA 01/2020
1	Serotonin (5 Hydroxytryptamine)IBA 01/2019
1	Uncoupling Protein 1IBA 01/2018
1	HDL CholesterolIBA 01/2017
1	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2017
1	Triglycerides (Triacylglycerol)IBA 01/2017
1	Gastrointestinal Hormones (Hormones, Gastrointestinal)IBA 01/2017
1	Sitagliptin Phosphate (Januvia)FDA Link 01/2017
1	Messenger RNA (mRNA)IBA 02/2016

Therapy/Procedure

19	Drug Therapy (Chemotherapy) 03/2024 - 03/2011
6	Therapeutics 01/2023 - 11/2019
5	Glycemic Control 12/2023 - 01/2020
2	Vagotomy 12/2023 - 04/2012
2	Self Administration (Administration, Self) 07/2014 - 09/2012
1	Analgesia 01/2023
1	Gastric Bypass (Roux-en-Y Gastric Bypass) 01/2017
1	Gastrectomy 01/2017